Best Peptides for Muscle Growth: What the Evidence Actually Shows

Let's start with honesty: if you're expecting steroid-level muscle gains from peptides, you'll be disappointed. Anabolic steroids produce 3-7 kg of lean mass in 12-16 weeks by directly activating androgen receptors. Growth hormone secretagogues — the most commonly discussed peptides for body composition — produce roughly 1-2 kg of lean mass gain over months, through indirect mechanisms. That said, peptides offer something steroids don't: a much safer risk-benefit profile, no HPG axis suppression, and benefits that extend beyond muscle (sleep, recovery, metabolic health). The question isn't whether peptides can replace steroids — they can't. The question is whether the more modest, physiologic effects of peptides are worth pursuing for your goals.

Growth hormone secretagogues stimulate your pituitary to release more of its own growth hormone, which in turn elevates IGF-1 — the downstream mediator of most anabolic effects. The main options: CJC-1295 + Ipamorelin is the most commonly prescribed combination. CJC-1295 extends the GHRH signal while ipamorelin selectively triggers GH release without affecting cortisol or appetite. Together they produce synergistic GH output — roughly 3-fold greater than either alone. Typically taken before bed to amplify the natural nocturnal GH pulse. MK-677 (ibutamoren) is the oral alternative. A randomized trial in healthy older adults showed it increased lean mass by approximately 1.1 kg over 2 years while preventing age-related lean mass loss. However, it did NOT improve strength or function. Its main downsides: significant appetite stimulation and potential insulin sensitivity impairment. Sermorelin and Tesamorelin are GHRH analogs. Tesamorelin has the most clinical data of any GH secretagogue — a meta-analysis of RCTs confirmed its effects on body composition in HIV-associated lipodystrophy, demonstrating meaningful lean mass preservation. A direct comparison study in older men found: testosterone alone increased lean mass by 3.0 kg; growth hormone alone increased it by 1.4 kg; the combination produced 3.9 kg. Testosterone also produced greater strength gains. This puts the GH secretagogue approach in perspective — helpful, but not in the same league as direct hormonal intervention.

IGF-1 LR3 and MGF (mechano growth factor) bypass the pituitary entirely, directly providing the growth factor that mediates GH's anabolic effects. IGF-1 LR3 has an extended half-life compared to natural IGF-1 and is discussed for localized muscle growth when injected near target muscles. These compounds are more potent than GH secretagogues for direct muscle effects but carry greater risk — particularly hypoglycemia and theoretical concerns about promoting growth of pre-existing cancers. They have very limited published human safety data and are considered advanced compounds, not appropriate for beginners.

Myostatin is a negative regulator of muscle growth — it tells muscles to stop growing. Follistatin inhibits myostatin, theoretically removing the brake on muscle development. Animals with myostatin mutations develop extraordinary musculature. In practice, the human evidence for follistatin supplementation is very limited. The myostatin pathway is well-characterized mechanistically, but translating genetic observations into therapeutic peptide interventions has proven difficult. Gene therapy approaches targeting myostatin have shown more promise than exogenous peptide administration. Follistatin remains speculative for muscle growth purposes.

BPC-157 and TB-500 don't build muscle directly, but they may support muscle growth indirectly by enabling more consistent, harder training through faster recovery. If an injury sidelines you for weeks, the muscle you don't build matters more than the marginal direct effect of any peptide. A systematic review of BPC-157 in orthopaedic sports medicine confirmed its preclinical promise for musculoskeletal recovery, while noting the absence of human RCTs. TB-500 has evidence for tissue repair through cell migration and angiogenesis. Neither has direct muscle-building evidence, but their recovery support role is why they're commonly discussed alongside body composition peptides.

An increasingly important context for peptides and muscle: the GLP-1 era. Semaglutide and tirzepatide produce dramatic weight loss, but 25-40% of that loss is lean mass — muscle, not just fat. This has created significant clinical interest in strategies to preserve lean mass during GLP-1 therapy. GH secretagogues are being discussed as complementary therapies during GLP-1-mediated weight loss to shift the ratio toward fat loss and muscle preservation. This isn't proven in controlled trials yet, but the mechanistic rationale is sound and clinical interest is growing.